It has been recently shown that EGFR inhibitors trigger adaptive responses through a TNF–JNK–Axl–ERK signaling axis in glioma cells.36 In a molecularly heterogeneous disease like GBM, this is likely but one of the many cellular and microenvironment dependent adaptive response mechanisms that occurs in response to EGFR inhibition. The gene discussed is EGFR; the disease is glioblastoma.